Use of mGluR5 (esp. AFQ056) in GI (esp. GERD)

Details for Australian Patent Application No. 2010201458 (hide)

Owner Novartis AG

Inventors Gasparini, Fabrizio; Pfannkuche, HansJurgen; Rouzade-Dominguez, MarieLaure

Agent Davies Collison Cave

Pub. Number AU-A-2010201458

Parent 2006268905

Filing date 13 April 2010

Wipo publication date 6 May 2010

International Classifications

A61K 31/4045 (2006.01)

A61K 31/165 (2006.01) - having aromatic rings, e.g. colchicine, atenolol, progabide

A61K 31/27 (2006.01)

A61K 31/4035 (2006.01)

A61K 31/4439 (2006.01)

A61K 31/47 (2006.01) - Quinolines

A61K 31/4709 (2006.01) - Non-condensed quinolines containing further heterocyclic rings

A61P 1/04 (2006.01) Drugs for disorders of the alimentary tract or the digestive system

A61P 13/00 (2006.01) Drugs for disorders of the urinary system

Event Publications

29 April 2010 Complete Application Filed

6 May 2010 Application Open to Public Inspection

  Published as AU-A-2010201458

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010201459-Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease

2010201457-3-[(2-{[4-(hexyloxycarbonylamino-iminomethyl)-phenylamino]-methyl}-1-methyl1H-benzimidazol-5-carbonyl)-pyridine-2 -yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament